Cisplatin-Induced Plasticity Causes CDK4/6 Inhibitor Cross-Resistance and Reveals HDACi Vulnerabil

Background and clinical context

Esophageal squamous cell carcinoma (ESCC) constitutes roughly 90% of esophageal cancer cases worldwide and carries poor outcomes, with overall survival below 20% as reported by the authors. Chemotherapy—commonly platinum-based regimens—remains a standard treatment, but acquired resistance to agents such as cisplatin is a major barrier to durable benefit and improved survival.

The study summarized here aimed to define the adaptive programs that establish and stabilize cisplatin resistance in ESCC and to explore whether those programs confer collateral vulnerabilities or cross-resistance to other therapies.

In vitro model and experimental approach

The authors used an in vitro model of cisplatin resistance to study how sustained platinum exposure changes cell state. They applied transcriptional and multiomic profiling to resistant clones and compared them to parental lines. A signature-based computational strategy was employed to nominate compounds able to reverse the resistant phenotype, and selected candidates were functionally validated.

Note: the abstract does not provide detailed experimental parameters (for example, number of clones, timelines of selection, cell lines used, or exact multiomic platforms). Those methodological details are not reported in the preprint abstract.

Heterogeneity of cisplatin-resistant states and DTP phenotype

Prolonged cisplatin exposure did not produce a single homogeneous resistant state. Instead, resistant cells occupied a continuum of adaptive transcriptional states. Most resistant clones acquired features reminiscent of drug-tolerant persisters (DTPs): stemness-associated markers and slow-cycling behavior. Importantly, this DTP-like phenotype persisted after cisplatin withdrawal and was accompanied by additional markers of resistance, suggesting that the initial adaptive state can consolidate into a stable, acquired-resistance state.

These observations characterize cisplatin resistance in ESCC as dynamic and plastic, with an epigenetic component that can persist beyond drug removal.

Cross-resistance to CDK4/6 inhibitors and cell-cycle dysregulation

Unexpectedly, the transcriptional and cellular reprogramming induced by cisplatin extended beyond platinum tolerance. Resistant clones displayed impaired cytostatic control and failed to suppress cell-cycle programs when treated with CDK4/6 inhibitors (CDK4/6i), indicating collateral cross-resistance to these agents.

Multiomic data supported this functional outcome: the expected cytostatic transcriptional responses to CDK4/6i were attenuated in cisplatin-resistant clones, consistent with a failure to enact CDK4/6i-mediated growth arrest.

Immune signaling alterations and immune-evasive features

Profiling revealed changes in immune and inflammatory signaling associated with the cisplatin-resistant state. Specifically, cisplatin-resistant clones showed:

• Attenuation of the immune and inflammatory signaling that would normally be induced by CDK4/6 inhibition.
• Upregulation of immune-evasive markers.
• Dysregulated basal interferon (IFN) pathway activation.

Collectively, these features were interpreted as an immune-evasive state that emerges as part of cisplatin-induced reprogramming and likely contributes to the inability of CDK4/6i to elicit their full immunomodulatory and cytostatic effects.

Identification and validation of HDAC inhibitors to reverse resistance

Using a signature-based computational approach, the authors identified histone deacetylase inhibitors (HDACi) as candidate agents to reverse the cisplatin-resistant transcriptional program. Functional validation experiments confirmed that combining HDACi with cisplatin restored sensitivity to levels comparable to parental cells. Furthermore, HDACi treatment enhanced the efficacy of CDK4/6 inhibitors in resistant clones.

These results support the hypothesis that epigenetic reprogramming underlies the resistant state and that epigenetic therapies can re-sensitize cells to both cisplatin and CDK4/6 inhibition.

Implications for therapy and mechanistic conclusions

From the data presented in the abstract, the authors conclude that cisplatin resistance in ESCC is:

• Reversible and epigenetically encoded, rather than an irreversible genetic change in all cases;
• Associated with a DTP-like, slow-cycling, stem-like cell state that can consolidate into stable resistance;
• Linked to collateral cross-resistance to CDK4/6 inhibitors through failure to engage cytostatic and immune-modulatory programs;
• Potentially targetable through HDAC inhibition, which can restore cisplatin sensitivity and potentiate CDK4/6i activity.

These mechanistic insights provide a rationale for testing HDACi-based combinations to overcome cisplatin-induced cross-resistance in ESCC.

Limitations and details not reported in the preprint abstract

The preprint abstract provides a concise overview of findings but does not include full experimental detail. Specifically, the abstract does not report:

• Exact cell lines, patient-derived models, or number of independent clones used in the study;
• Detailed multiomic platforms, the precise nature of the signatures used to nominate HDACi, or the statistical metrics for profiling results;
• In vivo validation, clinical correlation with patient samples, or safety/tolerability considerations for proposed combinations.

Because this report is a preprint, the findings have not undergone peer review. Full peer-reviewed publication will be necessary to evaluate methodological rigor, reproducibility, and translational potential.

Takeaway

The study identifies cisplatin-induced cellular plasticity in ESCC as a driver of cross-resistance to CDK4/6 inhibitors and highlights HDAC inhibitors as a strategy to reverse this epigenetically encoded, immune-evasive state. These preclinical findings warrant further validation and careful translational assessment before clinical application.